• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

EC Approves Australian Firm's Acquisition of Novartis Flu Vaccine Business


July 21, 2015.

The European Commission(EC) has approved the acquisition of Novartis's influenza vaccines business by CSL (Parkville, Victoria, Australia). 

Novartis's human influenza vaccines business manufactures and sells influenza vaccines primarily in the US, the EEA and Argentina. The two companies' activities overlap regarding seasonal influenza vaccines. The EC concluded that the proposed acquisition would not raise competition concerns, because the combined market shares of the parties will remain moderate and strong competitors will remain active in the market after the merger.

More information is available on the EC's competition website.

Related Videos